Mettler-Toledo International Inc. (MTD) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $1,341.53. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of MTD = $884.10 (-34.1% from the current price, the stock appears overvalued). Analyst consensus target is MTD = $1,499 (+11.8% upside).
Valuation: MTD trades at a trailing Price-to-Earnings (P/E) of 30.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.09.
Financials: revenue is $4.0B, +0.9%/yr average growth. Net income is $869M, growing at +0.2%/yr. Net profit margin is 21.6% (strong). Gross margin is 57.5% (-1.4 pp trend).
Balance sheet: total debt is $2.3B with negative equity of -$24M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.14 (adequate). Debt-to-assets is 63.1%. Total assets: $3.7B.
Analyst outlook: 8 / 19 analysts rate MTD as buy (42%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 33/100 (Fail), Growth 45/100 (Partial), Past 100/100 (Pass), Health 75/100 (Pass), Moat 76/100 (Pass), Future 40/100 (Partial), Income 85/100 (Pass).
